Sensitisation to staphylococcal enterotoxins and asthma severity: a longitudinal study in the EGEA cohort
- PMID: 31285304
- DOI: 10.1183/13993003.00198-2019
Sensitisation to staphylococcal enterotoxins and asthma severity: a longitudinal study in the EGEA cohort
Abstract
Introduction: Evidence is accumulating that Staphylococcus aureus plays an important role as disease modifier in upper and lower airway diseases. Sensitisation to S. aureus enterotoxins (SEs) was associated with an increased risk of severe asthma in previous cross-sectional studies, but evidence from longitudinal studies is lacking. We aimed to assess associations between SE-sensitisation and the subsequent risk for asthma severity and exacerbations.
Methods: This is a nested case-control study from the 20-year Epidemiological Study of the Genetics and Environment of Asthma (EGEA) cohort, including 225 adults (75 without asthma, 76 with mild asthma and 74 with severe asthma) in EGEA2 (2003-2007). For 173 of these individuals, SE-sensitisation was measured on samples collected 11 years earlier (EGEA1). Cross-sectional associations were conducted for EGEA1 and EGEA2. Longitudinal analyses estimated the association between SE-sensitisation in EGEA1 and the risk of severe asthma and asthma exacerbations assessed in the follow-up. Models were adjusted for sex, age, smoking, parental asthma/allergy and skin-prick test to house dust mite.
Results: SE-sensitisation varied between 39% in controls to 58% and 76% in mild and severe asthma, respectively, in EGEA1. An adjusted cross-sectional association showed that SE-sensitisation was associated with an increased risk of severe, but not for mild asthma. SE-sensitisation in EGEA1 was associated with severe asthma (adjusted OR 2.69, 95% CI 1.18-6.15) and asthma exacerbations (adjusted OR 4.59, 95% CI 1.40-15.07) assessed 10-20 years later.
Conclusion: For the first time, this study shows that being sensitised to SEs is associated with an increased subsequent risk of severe asthma and asthma exacerbations.
Copyright ©ERS 2019.
Conflict of interest statement
Conflict of interest: V. Siroux reports personal fees for lecturing from AstraZeneca, outside the submitted work. Conflict of interest: G. Holtappels has nothing to disclose. Conflict of interest: C. Pison reports non-financial support for meeting attendance from GSK France, AZ France, Boehringer Ingelheim and Novartis, outside the submitted work. Conflict of interest: R. Nadif has nothing to disclose. Conflict of interest: J. Bousquet reports personal fees for advisory board work, consultancy and lecturing from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva and Uriach, and owns shares in KYomed-INNOV, outside the submitted work. Conflict of interest: C. Bachert has nothing to disclose. Conflict of interest: I. Sintobin has nothing to disclose.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical